Last reviewed · How we verify

sulfadoxine-pyrimethamine intermittent preventive treatment

London School of Hygiene and Tropical Medicine · Phase 1 active Small molecule

sulfadoxine-pyrimethamine intermittent preventive treatment is a Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 1 development.

At a glance

Generic namesulfadoxine-pyrimethamine intermittent preventive treatment
SponsorLondon School of Hygiene and Tropical Medicine
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about sulfadoxine-pyrimethamine intermittent preventive treatment

What is sulfadoxine-pyrimethamine intermittent preventive treatment?

sulfadoxine-pyrimethamine intermittent preventive treatment is a Small molecule drug developed by London School of Hygiene and Tropical Medicine.

Who makes sulfadoxine-pyrimethamine intermittent preventive treatment?

sulfadoxine-pyrimethamine intermittent preventive treatment is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

What development phase is sulfadoxine-pyrimethamine intermittent preventive treatment in?

sulfadoxine-pyrimethamine intermittent preventive treatment is in Phase 1.

Related